The Menlo Park-based company is integrating epigenetic signatures into its rare disease diagnostics offering, with the new capability set to roll out automatically in early Q2 2026.
A University of Warwick study finds AI cancer detection models may rely on statistical correlations rather than true biomarker signals, raising concerns about reliability in clinical pathology applications.
Droplet Biosciences reports reducing genomic analysis time from days to hours for its LymphDetect test by adopting NVIDIA Parabricks GPU-accelerated software.
The AI companion analyzes up to five years of personal lab data within the company's patient portal to explain test results and identify health trends.
Washington University researchers have developed a blood test using p-tau217 protein levels to predict Alzheimer’s symptom onset within three to four years.
